Basic Information
Triumeq
Regulatory Information
EMEA/H/C/002754
August 31, 2014
June 26, 2014
35
December 10, 2024
Company Information
the netherlands
Van Asch van Wijckstraat 55 H 3811 LP Amersfoort
ViiV Healthcare BV
Active Substances Detail
dolutegravir sodiumlamivudineabacavir (as sulfate)
abacavir (as sulfate)
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Triumeq is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infected children of at least 3 months of age weighing at least 6 kg to less than 25 kg (see sections 4.4 and 5.1). Before initiating treatment with abacavir-containing products, screening for carriage of the HLA-B\*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin (see section 4.4). Abacavir should not be used in patients known to carry the HLA-B\*5701 allele. Triumeq is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infected adults, adolescents and children weighing at least 25 kg (see sections 4.4 and 5.1). Before initiating treatment with abacavir-containing products, screening for carriage of the HLA-B\*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin (see section 4.4). Abacavir should not be used in patients known to carry the HLA-B\*5701 allele.
Overview Summary
Triumeq is a medicine for treating infection with human immunodeficiency virus (HIV), the virus that causes acquired immunodeficiency syndrome (AIDS). It is used in adults, adolescents and children at least 3 months old who weigh at least 6 kg. Triumeq contains three active substances: dolutegravir, abacavir and lamivudine.